KARBE FRANK has filed 14 insider transactions across 2 companies since May 2023.
Most recent transaction: a disposition of 7526 shares of Cidara Therapeutics, Inc. ($CDTX) on January 07, 2026.
Activity breakdown: 1 open-market purchase and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | KARBE FRANK | Chief Financial Officer | D | Common Stock | 7526 | $221.50 | 43,125.0000 | 31,439,371 | 14.86% | 0.02% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | KARBE FRANK | Chief Financial Officer | D | Employee Stock Option (right to buy) | 115000 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.37% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | KARBE FRANK | Chief Financial Officer | D | Common Stock | 43125 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.14% |
| Dec. 10, 2025 | Cidara Therapeutics, Inc. | $CDTX | KARBE FRANK | Chief Financial Officer | F | Common Stock | 7290 | $219.60 | 50,562.0000 | 31,439,371 | 12.60% | 0.02% |
| June 3, 2025 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Not found | A | Common Stock | 10500 | $0.00 | 67,500.0000 | 63,176,210 | 18.42% | 0.02% |
| June 3, 2025 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Not found | A | Stock Option (Right to Buy) | 17500 | $0.00 | 17,500.0000 | 63,176,210 | 9999.99% | 0.03% |
| Feb. 24, 2025 | Cidara Therapeutics, Inc. | $CDTX | KARBE FRANK | Chief Financial Officer | A | Common Stock | 57500 | $0.00 | 57,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 24, 2025 | Cidara Therapeutics, Inc. | $CDTX | KARBE FRANK | Chief Financial Officer | A | Employee Stock Option (right to buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 13, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Not found | P | Common Stock | 12500 | $7.93 | 57,000.0000 | 64,627,847 | 28.09% | 0.02% |
| May 29, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Not found | A | Common Stock | 25000 | $10.16 | 44,500.0000 | 51,289,092 | 128.21% | 0.05% |
| May 23, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Not found | A | Stock Option (Right to Buy) | 17500 | $0.00 | 17,500.0000 | 51,289,092 | 50.00% | 0.03% |
| May 23, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Not found | A | Common Stock | 10500 | $0.00 | 19,500.0000 | 51,289,092 | 116.67% | 0.02% |
| May 25, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Director | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 0 | 9999.99% | 0.00% |
| May 25, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | KARBE FRANK | Director | A | Common Stock | 9000 | $0.00 | 9,000.0000 | 0 | 9999.99% | 0.00% |